GENPREX INC (GNPX) Stock Overview
USA - NASDAQ:GNPX - US3724462037 - Common Stock
GNPX Key Statistics, Chart & Performance
The current stock price of GNPX is 8.93 USD. In the past month the price increased by 7.49%. In the past year, price decreased by -90.29%.
GNPX Latest News, Press Relases and Analysis
GNPX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.54 | 402.92B | ||
| AMGN | AMGEN INC | 13.29 | 156.01B | ||
| GILD | GILEAD SCIENCES INC | 15.5 | 148.82B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.89 | 108.11B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.71 | 61.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 62.75B | ||
| ARGX | ARGENX SE - ADR | 89.85 | 50.95B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.08 | 34.53B | ||
| INSM | INSMED INC | N/A | 34.22B | ||
| NTRA | NATERA INC | N/A | 26.34B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.25B | ||
| BIIB | BIOGEN INC | 9.31 | 21.86B |
Related stock screener links
About GNPX
Company Profile
Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company is headquartered in Austin, Texas and currently employs 15 full-time employees. The company went IPO on 2018-03-29. The firm's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. Its oncology drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is developed in combination with approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). GPX-002 is being developed by the Company using the same construct for the treatment of both Type 1 diabetes and Type 2 diabetes. GPX-002 for Type 1 diabetes is designed to work by transforming alpha cells in the pancreas into functional beta-like cells.
Company Info
GENPREX INC
3300 Bee Cave Road, Suite 650-227
Austin TEXAS 78712 US
CEO: J. Rodney Varner
Employees: 15
Phone: 18777744679
GENPREX INC / GNPX FAQ
What does GENPREX INC do?
Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company is headquartered in Austin, Texas and currently employs 15 full-time employees. The company went IPO on 2018-03-29. The firm's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. Its oncology drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is developed in combination with approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). GPX-002 is being developed by the Company using the same construct for the treatment of both Type 1 diabetes and Type 2 diabetes. GPX-002 for Type 1 diabetes is designed to work by transforming alpha cells in the pancreas into functional beta-like cells.
What is the stock price of GENPREX INC today?
The current stock price of GNPX is 8.93 USD. The price decreased by -7.08% in the last trading session.
Does GENPREX INC pay dividends?
GNPX does not pay a dividend.
How is the ChartMill rating for GENPREX INC?
GNPX has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the upcoming earnings date for GENPREX INC?
GENPREX INC (GNPX) will report earnings on 2025-11-11, after the market close.
GNPX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to GNPX. When comparing the yearly performance of all stocks, GNPX is a bad performer in the overall market: 98.17% of all stocks are doing better.
GNPX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GNPX. While GNPX seems to be doing ok healthwise, there are quite some concerns on its profitability.
GNPX Financial Highlights
Over the last trailing twelve months GNPX reported a non-GAAP Earnings per Share(EPS) of -18.38. The EPS increased by 2.49% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -518.59% | ||
| ROE | -1320.11% | ||
| Debt/Equity | 0 |